目的 探討依達(dá)拉奉聯(lián)合卡馬西平治療腦梗死后繼發(fā)性癲癇的臨床療效。方法 選取2015年2月—2016年10月在海南省第二人民醫(yī)院接受治療的腦梗死后繼發(fā)性癲癇患者40例，根據(jù)治療方法的差別分為對照組（20例）和治療組（20例）。對照組患者口服卡馬西平片，0.2 g/次，2次/d。治療組在對照組的基礎(chǔ)上靜脈滴注依達(dá)拉奉注射液，30 mg加入生理鹽水100 mL中，2次/d。兩組患者均連續(xù)治療4周。比較兩組患者治療前后臨床療效、癇樣放電、累及導(dǎo)聯(lián)數(shù)和癲癇發(fā)作頻率變化。結(jié)果 治療后，對照組和治療組的總有效率分別為70.00%、85.71%，兩組總有效率比較差異具有統(tǒng)計學(xué)意義（P< 0.05）。治療后，兩組患者癇樣放電、累及導(dǎo)聯(lián)數(shù)和癲癇發(fā)作頻率均較治療前顯著降低，同組治療前后比較差異具有統(tǒng)計學(xué)意義（P< 0.05）；且治療組上述觀察指標(biāo)比對照組更低，兩組比較差異具有統(tǒng)計學(xué)意義（P< 0.05）。結(jié)論 依達(dá)拉奉聯(lián)合卡馬西平治療腦梗死后繼發(fā)性癲癇的臨床效果顯著，可有效控制癲癇發(fā)作及降低血清細(xì)胞因子水平，具有一定的臨床推廣應(yīng)用價值。

Objective To investigate the clinical efficacy of edaravone combined with carbamazepine in treatment of secondary epilepsy after cerebral infarction. Methods Patients (40 cases) with secondary epilepsy after cerebral infarction in the Second People's Hospital of Hainan Province from February 2015 to October 2016 were divided into control (20 cases) and treatment (20 cases) groups based on different treatments. Patients in the control group were po administered with Carbamazepine Tablets, 0.2 g/time, twice daily. Patients in the treatment group were iv administered with Edaravone Injection on the basis of the control group, 30 mg added into normal saline 100 mL, twice daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy, epileptiform discharges, involved lead number, and seizure frequency in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 70.00% and 85.71%, respectively, and there was difference between two groups (P < 0.05). After treatment, the epileptiform discharges, involved lead number and seizure frequency in two groups significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And these observation indicators in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Edaravone combined with carbamazepine can effectively control the seizure and reduce serum cytokine levels in treatment of secondary epilepsy after cerebral infarction, which has a certain clinical application value.